Adverse drug interactions in dental practice: Professional and educational implications

Journal of the American Dental Association

Volumn 130, Issue 1, 1999, Pages 47-54

  Moore, Paul A ^a   Gage, Tommy W ^b   Hersh, Elliot V ^c   Yagiela, John A ^d   Haas, Daniel A ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; DRUG; HYPNOTIC SEDATIVE AGENT; LOCAL ANESTHETIC AGENT; VASOCONSTRICTOR AGENT;

ARTICLE; DENTAL CARE; DENTAL EDUCATION; DRUG ANTAGONISM; DRUG INTERACTION; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; HUMAN; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANALGESICS; ANESTHETICS, LOCAL; ANTI-BACTERIAL AGENTS; DENTAL CARE; DRUG ANTAGONISM; DRUG INTERACTIONS; DRUG SYNERGISM; EDUCATION, DENTAL; HUMANS; HYPNOTICS AND SEDATIVES; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; VASOCONSTRICTOR AGENTS;

EID: 0032615445     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.1999.0028     Document Type: Article

References (25)

1. Burt BA, Eklund SA. Dentistry, dental practice, and the community. 4th ed. Philadelphia: Saunders; 1992:11-22.
2. Marcus SE, Drury TF, Brown LJ, Zion GR. Tooth retention and tooth loss in the permanent dentition of adults: United States, 1988-1991. J Dent Res 1996;75(special issue):684-95.
3. U.S. Public Health Service. Healthy people 2000: National health promotion and disease prevention objectives. Washington, D.C.: U.S. Department of Health and Human Services; 1991. DHHS publication (PHS) 91-50212.
4. "Dear health care professional" letter. Roche Laboratories, 6/12/98; Internet publication by the FDA. Available at: "http://www.fda.gov/medwatch/safety/1998/ posico2.htm". Accessed July 15, 1998.
5. Institute of Medicine Committee on the Future of Dental Education. Dental education at the crossroads: Challenges and changes. In: Field MJ, ed. Washington, D.C.: National Academy Press; 1995.
6. The top 200 drugs. American Druggist 1997; Feb:30-7.
7. Drug topics red book 1998. Montvale, N.J.: Medical Economics Company; 1998:132.
8. Wright JW. Drug interactions. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Clinical pharmacology. 3rd ed. New York: McGraw-Hill; 1992:1012-21.
9. Physicians' desk reference. 52nd ed. Montvale, N.J.: Medical Economics Company; 1999.
10. Wynn RL, Meiller TF, Crossley HL. Drug information handbook for dentistry. 4th ed. Hudson, Ohio: Lexi-Comp; 1998.
11. Gage TW, Pickett FA. Dental drug reference. 4th ed. St. Louis: Mosby-Year Book; 1999.
12. Rizack MA. The medical letter handbook of adverse drug interactions. New Rochelle, N.Y.: Medical Letter Inc.; 1998.
13. Wynn RL. Internet Web sites for drug information. Gen Dent 1998;46(1):12-8.
14. Yagiela JA, Picozzi A. General mechanisms of drug interactions. In: Yagiela JA, Neidle EA, Dowd FJ, eds. Pharmacology and therapeutics for dentistry. 4th ed. St. Louis: Mosby-Year Book; 1998:61-8.
15. Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269:2765-8.
16. Protecting the identities of reporters of adverse events and patients: preemption of disclosure rules. Fed Regist 1995;60:16961-8.
17. Baum C, Kweder SL, Anello C. The spontaneous reporting system in the United States. In: Strom BL, ed. Pharmacoepidemiology. 2nd ed. New York: Wiley & Sons; 1994.
18. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997;61:395-400.
19. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995;29(9):906-17.
20. Honig P, Wortham D, Lazarev A, Cantilena LR. Pharmacokinetics and cardiac effects of terfenadine in poor metabolizers receiving concomitant grapefruit juice in humans (abstract). Clin Pharmacol Ther 1995;57:185.
21. Tatro DS, ed. Drug interaction facts. St. Louis: Facts and Comparisons; 1997:xiv-xvii.
22. Ciancio SG, ed. ADA guide to dental therapeutics. Chicago: ADA Publishing Co., Inc.; 1998.
23. Schein JR. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995;29:1139-47.
24. Slavkin HC. Benefits and risks of medications: challenges for the 21st century. JADA 1997;128:1157-60.
25. Mandelli M, Tognoni G, Garattini S. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 1978;3:72-91.